The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Randomized phase II study of pemetrexed versus gefitinib in previously treated patients with advanced non-small cell lung cancer.
Young Saing Kim
No relevant relationships to disclose
Eun Kyung Cho
No relevant relationships to disclose
Sun Jin Sym
No relevant relationships to disclose
Junshik Hong
No relevant relationships to disclose
Inkeun Park
No relevant relationships to disclose
Hee Kyung Ahn
No relevant relationships to disclose
Jeong Woong Park
No relevant relationships to disclose
Sung Hwan Jung
No relevant relationships to disclose
Jinny Park
No relevant relationships to disclose
Jae Hoon Lee
No relevant relationships to disclose
Dong Bok Shin
No relevant relationships to disclose